ストックスクリーナーアプリを入手
1.59
3.64%
-0.06
アフターアワーズ：
1.65
0.06
+3.77%
Aclaris Therapeutics Inc (ACRS) 最新ニュース
Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion - Investing.com India
Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion By Investing.com - Investing.com UK
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MSN
Common Warts Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail
Scotiabank Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. to Host Earnings Call - accessnewswire.com
Scotiabank Initiates Coverage of Aclaris Therapeutics (ACRS) with Sector Outperform Recommendation - Nasdaq
Scotiabank sets Aclaris stock target at $15 with new rating - Investing.com
Scotiabank sets Aclaris stock target at $15 with new rating By Investing.com - Investing.com UK
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - Simply Wall St
Cantor Fitzgerald Predicts ACRS FY2025 Earnings - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $11.00 - Defense World
Aclaris Therapeutics (NASDAQ:ACRS shareholders incur further losses as stock declines 12% this week, taking three-year losses to 88% - Simply Wall St
Cantor Fitzgerald Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to Strong-Buy - Defense World
Aclaris Therapeutics plans $300M mixed shelf offering - MSN
Aclaris Therapeutics to Participate in Two March Healthcare Conferences - GlobeNewswire
Will Aclaris Therapeutics Reveal New Pipeline Updates at March Healthcare Conferences? - StockTitan
This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year - Yahoo Finance
JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.
Aclaris Therapeutics Inc (NASDAQ: ACRS): Hidden Gems In A Time Of Volatility - Stocks Register
Hair Loss Treatment Market Hits New High | Major Giants Follica, Theradome, Histogen, Aclaris Therapeutics - Newstrail
Q1 Earnings Forecast for ACRS Issued By Leerink Partnrs - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results - MarketBeat
Aclaris Reports 2024 Financial Results and Sets Stage for Transformative 2025 - MyChesCo
Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Aclaris Therapeutics Reports 2024 Financial Results - TipRanks
Aclaris: Q4 Earnings Snapshot - CT Insider
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates - MSN
Aclaris Therapeutics Inc earnings missed by $0.72, revenue topped estimates - Investing.com
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
Aclaris Therapeutics reports Q4 EPS ($1.01), consensus (38c) - TipRanks
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
Aclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement Plan - MSN
Aclaris Therapeutics Inc (ACRS) Becoming More Attractive for Investors - Knox Daily
Aclaris Therapeutics (ACRS) Projected to Post Quarterly Earnings on Tuesday - Defense World
Aclaris Therapeutics (ACRS) Expected to Announce Earnings on Tuesday - MarketBeat
Common Warts Market to Expand Significantly by 2034, States - openPR
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 15.6% in January - MarketBeat
Peapod Lane Capital LLC Takes $1 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Growth in Short Interest - Defense World
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - GlobeNewswire
Clinical Data: Revolutionary Dual-Target Drug Shows Promise for Multiple Autoimmune Conditions - StockTitan
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
3.20%
1.03%
大文字化:
|
ボリューム (24 時間):